

ACCOMPANYING PAPERS:

Accompanying this response is a Declaration signed by Amy J. Weiner (Exhibits A & B). Also, excerpts from Barrett, J. T., Basic immunology and its medical application, 2nd edition, pp. 14-17 (1980) are attached.

AMENDMENTS

IN THE SPECIFICATION

Please amend the specification as follows:

Page 7, line 12, change "the" to -- that --.

Page 21, line 29, change "Tween 80 (TM)" to -- Tween® 80 (sorbitan monooleate) -- and "Span" to -- Span® --.

Page 22, line 1, change "(TM)" to -- (sorbitan trioleate) --;

line 4, change "Tween 80(TM)" to -- Tween® 80 (sorbitan monooleate) --, change "pluronic" to -- Pluronic® --, delete "-blocked polymer" and after "L121" insert -- (methyl oxirane polymer (C₃H₆O. C₂H₄O)_x) --;

line 7, change "Tween 80(TM)" to -- Tween® 80 (sorbitan monooleate) --;

line 10, change "Stimulon™" to -- Stimulon® --.

Page 25, line 21, change "D." to -- F. --.

Page 26, line 20, change "E." to -- G. --.

Page 28, line 12, change "F." to -- H. --.

Page 32, line 22, change "Tween(TM)" to -- Tween® 80 (sorbitan monooleate) --.

~~Page 33~~, line 3, change "Triton X-100(TM)" to -- Triton® X-100 (octylphenoxy poly thoxy ethanol (EO-9-10)).

~~Page 34~~, line 1, change "Sephadex(TM)" to -- Sephadex® (epichlorohydrin cross-linked dextran gel filtration beads) --;

~~line 2~~, change "thiomersal" to -- thimerosal --;

~~line 10~~, change "Sephadex(TM) PD-10" to -- Sephadex® PD-10 --.

~~Page 35~~, line 5, change both occurrences of "Milli Q" to -- Milli Q® --.

~~Page 36~~, line 9, change "SEP-PAKs(TM)" to -- SEP-PAKs® --;

~~lines 11, 12, and 13~~, change "Milli Q" to -- Milli Q® -- ; and

~~lines 17, 19, and 20~~, change "PAKs(TM)" to -- PAKs® --.

~~Page 37~~, line 9, change "Sephadex PD-10" to -- Sephadex® PD-10 --.

~~Page 40~~, line 7, "94°" should read -- 94°C, an --; and

C, an

~~line 9~~, change "extension" to -- annealing --.

Please amend the claims as follows:

1. (twice-amended) A method for passively immunizing an individual for treatment of hepatitis C virus (HCV) infection comprising administering to the individual an antibody composition comprising [an] a substantially isolated antibody capable of recognizing and binding to a conserved motif of amino acids [sequence] of the formula

aa1-aa2-aa3-aa4-aa5-aa6

wherein